EPS for Celldex Therapeutics, Inc. (CLDX) Expected At $-0.12

July 14, 2018 - By Jimmy Baldridge

Analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report $-0.12 EPS on August, 14.They anticipate $0.11 EPS change or 47.83 % from last quarter’s $-0.23 EPS. After having $-0.19 EPS previously, Celldex Therapeutics, Inc.’s analysts see -36.84 % EPS growth. The stock increased 0.12% or $0.0006 during the last trading session, reaching $0.5206. About 1.26 million shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 79.56% since July 14, 2017 and is downtrending. It has underperformed by 92.13% the S&P500.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Among 4 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Celldex Therapeutics had 4 analyst reports since March 8, 2018 according to SRatingsIntel. Leerink Swann maintained it with “Market Perform” rating and $3 target in Thursday, March 8 report. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Hold” rating by Jefferies on Thursday, March 8. Cantor Fitzgerald maintained the stock with “Neutral” rating in Tuesday, April 17 report. The rating was downgraded by Cowen & Co to “Hold” on Monday, April 16.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $74.65 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It currently has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

More recent Celldex Therapeutics, Inc. (NASDAQ:CLDX) news were published by: Fool.com which released: “Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics” on June 29, 2018. Also Seekingalpha.com published the news titled: “Celldex Therapeutics Salvage Value” on June 15, 2018. Nasdaq.com‘s news article titled: “How David Gardner’s Biggest Losers Demonstrate Why Long-Term Investing Wins” with publication date: July 02, 2018 was also an interesting one.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: